{
    "clinical_study": {
        "@rank": "55262", 
        "acronym": "AME", 
        "arm_group": {
            "arm_group_label": "[14C]-LX4211", 
            "arm_group_type": "Experimental", 
            "description": "400 mg LX4211 administered orally"
        }, 
        "brief_summary": {
            "textblock": "This phase 1 study is to evaluate the pharmacokinetics (PK), metabolism, routes and extent\n      of elimination of a single oral dose of 400 mg [14C]LX4211 to healthy male subjects"
        }, 
        "brief_title": "Study to Determine the Absorption, Metabolism, and Excretion of [14C]LX4211 in Healthy Male Subjects", 
        "completion_date": {
            "#text": "May 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adults \u226518 to \u226455 years of age\n\n          -  Vital signs at Screening in the following ranges: systolic blood pressure, 90-140 mm\n             Hg; diastolic blood pressure, 50-90 mm Hg; heart rate, 50-100 bpm\n\n          -  Body mass index (BMI) \u226518 and \u226435 kg/sq m\n\n          -  Historically able to produce a minimum of 1 bowel movement per day\n\n          -  Willing and able to provide written informed consent\n\n        Exclusion Criteria:\n\n          -  Female\n\n          -  Receipt of any investigational drug within 30 days prior to Dosing, or\n             investigational protein or antibody-based therapeutic agents within 3 months prior to\n             Screening\n\n          -  Prior exposure to LX4211\n\n          -  Use any tobacco product within 2 months prior to Screening and while participating in\n             the study (Day -1 through Discharge)\n\n          -  History of bariatric surgery or any other GI surgery that may induce malabsorption\n\n          -  History of any major surgery within 6 months prior to Screening\n\n          -  History of renal or hepatic disease, or significantly abnormal kidney or liver\n             function tests at Screening\n\n          -  History of any clinically relevant psychiatric, renal, hepatic, pancreatic,\n             cardiovascular, neurological, hematological, or GI abnormality\n\n          -  History of any active infection within 14 days prior to Dosing\n\n          -  History of alcohol or substance abuse within 2 years prior to Dosing\n\n          -  History of human immunodeficiency virus (HIV), hepatitis B, or hepatitis C\n\n          -  Donation or loss of >400 mL of blood or blood product within 3 months of Dosing\n\n          -  Positive urine glucose at Screening\n\n          -  Positive urine screen for drugs of abuse at Screening or Day -1\n\n          -  Positive breath test for alcohol at Screening or Day -1\n\n          -  Participation in >1 other radiolabeled investigational study drug trial within 12\n             months prior to Day -1\n\n          -  Exposure to significant radiation within 12 months prior to Day -1"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "8", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 21, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01818232", 
            "org_study_id": "LX4211.1-108-NRM", 
            "secondary_id": "LX4211.108"
        }, 
        "intervention": {
            "arm_group_label": "[14C]-LX4211", 
            "intervention_name": "[14C]-LX4211", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "June 17, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Madison", 
                    "country": "United States", 
                    "state": "Wisconsin", 
                    "zip": "53704"
                }, 
                "name": "Lexicon Investigational Site"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 1, Open-label, Nonrandomized, Single Dose Study to Evaluate the Absorption, Metabolism, and Excretion of [14C]-LX4211, Following Oral Administration, in Healthy Male Subjects", 
        "overall_official": {
            "affiliation": "Lexicon Pharmaceuticals, Inc.", 
            "last_name": "Ikenna Ogbaa, M.D.", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Area Under Curve (AUC)", 
            "safety_issue": "No", 
            "time_frame": "Day 1: predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 hours post-dose"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01818232"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Number of subjects experiencing an adverse event", 
                "safety_issue": "Yes", 
                "time_frame": "Day 1 through discharge"
            }, 
            {
                "measure": "Urinary recovery of radioactivity", 
                "safety_issue": "No", 
                "time_frame": "predose through 24 hours"
            }, 
            {
                "measure": "Fecal recovery of radioactivity", 
                "safety_issue": "No", 
                "time_frame": "predose through 24 hours"
            }, 
            {
                "measure": "Whole blood and plasma concentration of total radioactivity", 
                "safety_issue": "No", 
                "time_frame": "predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 hours post-dose"
            }
        ], 
        "source": "Lexicon Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Lexicon Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}